-transparent.png){kind=logo}
Schizophrenia, a devastating disease characterized by a combination of various types of disturbed behaviors, thoughts, and feelings, may likewise be heterogeneous in etiology. Recent advances in neuroscience and psychopharmacology have suggested a wide array of competing mechanisms that may be involved in schizophrenia, including but not limited to deficits in one or more neurotransmitters and second messenger systems (e.g., dopamine, serotonin, gamma-aminobutyric acid, glutamate, and noradrenaline), neurodevelopmental defects in brain circuitry, and viral infection. Psychiatric genetic studies indicate that schizophrenia is a disorder with multifactorial inheritance. Since cerebral metabolic activity reflects regional brain work for all neurotransmitter systems, imaging metabolism directly with fluorodeoxyglucose and indirectly with blood flow and hemoglobin oxygen saturation can provide information about the functional neuroanatomy of a deficit in individual patients and allow patients to be grouped into more homogeneous subgroups for intensive study. This review summarizes metabolic imaging studies in schizophrenia over the past decade.
M S Buchsbaum, and
E A Hazlett
January 1991,
Acta psychiatrica Belgica,
M S Buchsbaum, and
E A Hazlett
January 1995,
Clinical neuroscience (New York, N.Y.),
M S Buchsbaum, and
E A Hazlett
April 1988,
Psychiatry research,
M S Buchsbaum, and
E A Hazlett
October 1987,
Annals of neurology,
M S Buchsbaum, and
E A Hazlett
October 1994,
The Journal of clinical psychiatry,
M S Buchsbaum, and
E A Hazlett
March 1990,
Harefuah,
M S Buchsbaum, and
E A Hazlett
January 1986,
Seminars in nuclear medicine,
M S Buchsbaum, and
E A Hazlett
May 2014,
Human brain mapping,
M S Buchsbaum, and
E A Hazlett
December 2001,
IUBMB life,
M S Buchsbaum, and
E A Hazlett
November 2006,
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
